#Lipoblastoma

[rohans18]

Benign and Malignant Soft Tissue Tumors Treatment Market CAGR, Trends, Top Players, Analysis, Industry Size - Forecast 2029

Global Benign and Malignant Soft Tissue Tumors Treatment Market, By Types Benign Schwannoma, Desmoid Tumor, Lipoblastoma, Lipoma, Solitary, Uterine Leiomyoma, Clear Cell Sarcoma, Dermatofibrosarcoma Protuberans, Ewing Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Liposarcoma, Myxoid, Liposarcoma, Well Differentiated, Alveolar Rhabdomyosarcoma, Synovial Sarcoma, Others), Treatment (Medical Therapy, Surgical Therapy, Postoperative Therapy, Long Term Monitoring, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

In the consistent Benign and Malignant Soft Tissue Tumors Treatment market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Benign and Malignant Soft Tissue Tumors Treatment industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Benign and Malignant Soft Tissue Tumors Treatment market report brings precise and exact market research information that drives business into the right direction.

Key Players

Cyanotech Corporation (U.S.)

I.D. - Parry (India) Limited (India)

BlueBioTech International GmbH (Germany)

Algatech Ltd. (Israel)

Tianjin Norland Biotech Co., Ltd. (China)

AlgaeCan Biotech Ltd. (Canada)

AstaReal AB (Sweden)

Yunnan Alphy Biotech Co., Ltd. (China)

Fenchem (China)

Piveg, Inc. (U.S.)

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-benign-and-malignant-soft-tissue-tumors-treatment-market

The research studies entailed in the winning Benign and Malignant Soft Tissue Tumors Treatment market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Benign and Malignant Soft Tissue Tumors Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[ourhaileydavies]

Juniper Publishers-Open Access Journal of Head Neck & Spine Surgery

A Rare Origin of Supraclavicular Mass in a Ten-Month-Old Child: Case Report of Lipoblastoma

Authored by Salama Khadija

Introduction

Lipoblastoma is a rare benign tumor arising from embryonic white fat which occurs in the early childhood and accounts for up to 30% of adipocytic tumors in children while true lipomas account for 60% of all cases [1]. It usually arises on the extremities and considered as a rare cause of a pediatric head and neck masses. To notice that less than 100 cases of lipoblastomas- all locations- have been reported in literature till now, whereas, head and neck involvement has been reported in only very few cases [2]. In the Hospital University Ibn Rochd, we admitted a ten month child with lipoblastoma arising from the supraclavicular area. A significant risk of invading the subclavian vessels, the brachial plexus and the thoracic duct in contact was near.

Case Report

A 10-month-old girl, with no relevant medical or surgical history, brought by her parents to the outpatient ENT department for painless left side neck mass growing progressively over the last 5 months, with no sign of compression, in a context of a conservation of general state. On physical examination, there was a painless, non-pulsatile, solid to firm left-sided cervical mass in the supraclavicular area measuring approximately 6cm of large diameter, fixed to the underlying structures, mobile relative to the overlying skin (Figure 1), with no inflammatory signs neither was a lymph node hypertrophy. The rest of clinical examination was within normal limits with no abnormal laboratory findings. Ultrasonography revealed a homogeneous, hyperechogenic mass with a peripheral vascularization, plunging into the left supraclavicular area evocative of either hemangioma or lipoblastoma. We completed by neck CT scan which revealed a well limited supraclavicular lobulated mass encroaching upon the sternocleidomastoid muscle, with a greasy density similar to that of the subcutaneous fat in which some enhancement was visible, crossed by internal septa, measuring 63x42x40mm.The mass came into contact with the clavicle without bone lysis, also with the subclavian blood vessels which remain permeable (Figure 2). The biopsy of the mass confirmed the diagnosis of lipoblastoma. A multidisciplinary surgery (Otorhinolaryngologist and Pediatric surgeon) was considered  

Per-operatively, the lesion was found to be well encapsulated fixed to clavicle, in contact with the branches of the brachial plexus posteriorly. Complete surgical resection of the mass with an under-periosteum dissection without cleidotomy was performed, the subclavian vein was tightly adherent to the mass which was delicately dissected, and the brachial plexus was seen and preserved (Figure 3). Histological examination showed an adipose lesion, divided into lobules by fibrous septa. The adipose tissue consisted of mature adipocytes of various size and few lipoblasts. These findings were compatible with lipoblastoma. The postoperative period was uneventful, one-year follow-up found no local recurrence.

Discussion

The term “lipoblastoma” was coined by Jaffe [3] in 1926 to describe an atypical lipomatous lesion that consisted of cells resembling embryonic white fat [3]. This term was intended to differentiate these lesions from common lipomas, which contain no lipoblasts. Chung & Enzinger [1] described two forms: lipoblastoma as a localized circumscribed type which represents approximately 70% of cases and lipoblastomatosis for the diffuse multicentric variant (about 30% of cases) which is a deeply located, poorly circumscribed lesion with infiltrative growth pattern that may affect surrounding muscle structures, this latter is more difficult to remove completely [1,4]. It commonly arises from the extremities (36 72%) and the trunk (20 50%), and less commonly in the head and neck (10 15%) [2]. Within this latter, the neck is the most common location, other locations may also be included as the parotid gland, cheek, skin and orbit [5,6]. It occurs exclusively in infants and children, with 90% of the cases in children under 3 years of age, with the median age of onset being 1 year. It shows a male preponderance (3:1) and a rapid growth rate [6].

Usually, it presents as a painless, progressively growing mass if localized superficially. Symptoms are related to the location and size or mass effect of the lesion. Its rapid growth may cause compressive symptoms such as an airway obstruction and respiratory symptoms that have been described in patients with pleural, mediastinal, pulmonary, and lower neck lipoblastomas [5,7].  

The presumptive diagnosis is performed by imaging: Ultrasonography, CT or MRI being more sensitive by showing the characteristics of the mass components [7]. Imaging exhibits the precise location of the lesion and its extent to the surrounding structures which helps in planning surgical resection, however, it cannot differentiate lipomatous tumors which make these ones radiologically indistinguishable [8]. Therefore, the definitive diagnosis is made histologically. Moreover, recent cytogenetic analysis revealed specific chromosomal abnormalities in adipose tissue tumors which may lead to accurate diagnosis [2,9].  

The most important differential diagnosis of lipoblastoma is myxoid liposarcoma. Since the distinction between the twoentities cannot be performed on imaging. The age of the patient is significant. Liposarcomas are extremely rare in patients less than 10 years of age. Histology can differentiate on the basis of architectural changes and cytogenetic analysis displays a characteristic rearrangement of the long arm of chromosome 8 (8q11-13) affecting PLAG1 in lipoblastoma, when myxoid liposarcoma shows a t(12;16) (q13;p11) translocation [10-13].

Dilley et al. [14] had reviewed 24 patients who presented to a single institution over a 15 year period. Of these 24 patients, only 4 had tumor in the head and neck region. The tumor may present as a focal or diffuse lesion with the former being more common. It has also been mentioned that focal lesions usually do not require further surgery following initial resection. Patients with lipoblastoma may present with various symptoms depending upon its site. Rasmussen et al. [15], mentioned a case of cervical lipoblastoma causing intermittent airway obstruction. Farrugia et al. [16] reported another case of lipoblastoma of the neck which was presented as a rapidly enlarging mass, mimicking cystic hygroma. Eveline Bruyeera [6] reported three cases of head and neck lipoblastoma. The outcome of three patients was favorable after complete surgical resection. K Premkumar [2] recently reported another case of an extensive tumor located over the nape of the neck that causes a restriction of neck movement

Lipoblastoma exhibits a propensity to invade locally. If not excised early, it may enlarge and infiltrate the various surrounding structures. Various pressure symptoms may occur which can lead to life threatening complications as noted hereinbefore [2].  

The mainstay of treatment is complete non-mutilating resection of the tumor to avoid recurrence. If the entire tumor cannot be safely removed at the time of initial resection, a staged approach is recommended. [17] The prognosis is excellent, and the recurrence rate is less than 25% being largely attributed to the infiltrative form ‘lipoblastomatosis’. The evolution is unpredictable, spontaneous resolution and maturation into lipoma may occur, but metastases still not reported so far [17,18].

Conclusion

Head and neck lipoblastoma are a rare childhood tumor, usually presenting as a progressive painless mass, rarely causing airway obstruction, nerve or vascular compression. Through our case, we aimed to shed light on lipoblastomas as a differential diagnosis of rapidly growing soft fatty masses of children within this region.

For more articles in Open access Journal of Head Neck & Spine Surgery | Please click on: https://juniperpublishers.com/jhnss/index.php

For more about Juniper Publishers | Please click on: https://juniperpublishers.com/pdf/Peer-Review-System.pdf

[taliemsite-blog]

(via Oncologic Imaging Soft Tissue Tumors) The vast majority of soft tissue masses that present to physicians are benign lesions. The incidence of benign soft tissue tumors is estimated to outnumber malignant tumors by a factor of at least 100 (Balach et al. 2011). Unlike their intraosseous counterparts, it is often not possible to establish a meaningful  differential diagnosis for soft tissue tumors or reliably  determine if they are benign or malignant. In these cases, knowledge of the soft tissue tumor’s prevalence, along with the patient’s age and the lesion’s location, will allow a suitably ordered differential diagnosis (Kransdorf 1995). Embryonal   rhabdomyosarcoma occurs most often in children under 10 years of age ,while synovial sarcoma is most prevalent in adolescents and young adults. Most soft tissue sarcomas, including undifferentiated  pleomorphic sarcoma, liposarcoma, and leiomyosarcoma, dominate in the elderly. The most common tumors in childhood and adolescence are, in order of prevalence, hemangioma, fbrous hamartoma, granuloma annulare, lipoblastoma, fbrosarcoma, and rhabdomyosarcoma. The most common tumors in adults are lipoma, liposarcoma, and myxofbrosarcoma (De Schepper and Bloem 2007).

[cancersfakianakis1]

Fine-needle aspiration of lipoblastoma: Cytological, molecular, and clinical features

BACKGROUND

Lipoblastomas are rare, benign adipocytic tumors that present mostly during infancy. In about 70% of cases, these tumors carry abnormalities in chromosome 8, mainly leading to rearrangements of the PLAG1 gene.

METHODS

We report a series of histologically proven lipoblastomas with previous fine-needle aspiration (FNA) cytology from 9 patients (n = 10 samples) and describe their clinical, cytological, and molecular features.

RESULTS

Our cohort included 5 boys and 4 girls (median age, 2.5 years [range, 10 months to 13 years]) who presented with soft tissue masses in the thorax (n = 3), abdomen (n = 2), axilla (n = 2), and thigh (n = 2). In 1 patient, the FNA diagnosis was inconclusive due to hypocellularity, and in another patient a diagnosis of benign lipomatous tumor was made. In the remaining 8 samples (one of which confirmed relapse), a correct preoperative FNA diagnosis was rendered. Smears were hypo- to moderately cellular and contained fragments of mature adipose tissue with thin branching vessels admixed with some lipoblasts in a myxoid matrix. Spindle cells and naked oval nuclei with no atypia were observed in the background. Of the 4 patients tested for PLAG1 rearrangement using FISH probes, 3 harbored this alteration (1 was made on a FNA smear and 1 was made in a tumor imprint). All the patients are alive and well, except for 1 patient with a retroperitoneal tumor who, after an initial incomplete excision, died of local disease progression.

CONCLUSION

FNA, especially if used together with molecular biology techniques (eg, PLAG1 FISH analysis), is a reliable and accurate diagnostic tool. Cancer Cytopathol 2017. © 2017 American Cancer Society.

http://ift.tt/2xy3seA

[rohans18]

Benign and Malignant Soft Tissue Tumors Treatment Market Key Players, Outlook and Forecast 2029

Global Benign and Malignant Soft Tissue Tumors Treatment Market, By Types Benign Schwannoma, Desmoid Tumor, Lipoblastoma, Lipoma, Solitary, Uterine Leiomyoma, Clear Cell Sarcoma, Dermatofibrosarcoma Protuberans, Ewing Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Liposarcoma, Myxoid, Liposarcoma, Well Differentiated, Alveolar Rhabdomyosarcoma, Synovial Sarcoma, Others), Treatment (Medical Therapy, Surgical Therapy, Postoperative Therapy, Long Term Monitoring, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Benign and Malignant Soft Tissue Tumors Treatment marketing report. The report has a lot to offer to both established and new players in the Benign and Malignant Soft Tissue Tumors Treatment industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Benign and Malignant Soft Tissue Tumors Treatment market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

Hoffmann-La Roche Ltd. (Switzerland)

Mylan N.V. (U.S.)

Teva Pharmaceutical Industries Ltd. (Israel)

Sanofi (France)

Pfizer Inc. (U.S.)

GSK plc (U.K.)

Novartis AG (Switzerland)

Bayer AG (Germany)

Lilly (U.S.)

Merck & Co., Inc. (U.S.)

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-benign-and-malignant-soft-tissue-tumors-treatment-market

With the help of credible Benign and Malignant Soft Tissue Tumors Treatment market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Benign and Malignant Soft Tissue Tumors Treatment market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Benign and Malignant Soft Tissue Tumors Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[rohans18]

Benign and Malignant Soft Tissue Tumors Treatment Market CAGR, Trends, Top Players, Analysis, Industry Size - Forecast 2029

Global Benign and Malignant Soft Tissue Tumors Treatment Market, By Types Benign Schwannoma, Desmoid Tumor, Lipoblastoma, Lipoma, Solitary, Uterine Leiomyoma, Clear Cell Sarcoma, Dermatofibrosarcoma Protuberans, Ewing Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Liposarcoma, Myxoid, Liposarcoma, Well Differentiated, Alveolar Rhabdomyosarcoma, Synovial Sarcoma, Others), Treatment (Medical Therapy, Surgical Therapy, Postoperative Therapy, Long Term Monitoring, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

The consistent Benign and Malignant Soft Tissue Tumors Treatment market report analyzes many points that help businesses to solve the toughest questions in less time. The major topics of this business report are global growth trends, market share by manufacturers, market size by type, market size by application, production by region, consumption by region, company profiles, market forecast, value chain and sales channels analysis, opportunities & challenges, threat and affecting factors. The report gives market definition in the form of market driving factors and market restraints which helps estimating the demand of particular product depending on several aspects. Benign and Malignant Soft Tissue Tumors Treatment market survey report studies the global market status and forecast, categorizes the global market size, market value & market volume by key players, type, application, and region.

Key Players

Hoffmann-La Roche Ltd. (Switzerland)

Mylan N.V. (U.S.)

Teva Pharmaceutical Industries Ltd. (Israel)

Sanofi (France)

Pfizer Inc. (U.S.)

GSK plc (U.K.)

Novartis AG (Switzerland)

Bayer AG (Germany)

Lilly (U.S.)

Merck & Co., Inc. (U.S.)

Sun Pharmaceutical Industries Ltd. (India)

Aurobindo Pharma (India)

Lupin (India)

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-benign-and-malignant-soft-tissue-tumors-treatment-market

One of the principal objectives of a high-ranking Benign and Malignant Soft Tissue Tumors Treatment industry report is to analyze and study the global sales, value, status, and forecast. The market report also analyzes the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. The report assists to define, describe and forecast the market by type, application and region. It estimates the region that is foretold to create the most number of opportunities in the global Benign and Malignant Soft Tissue Tumors Treatment market. This market research report comprises of estimations of CAGR values which are quite significant and aids businesses to decide upon the investment value over the time period. An insightful Benign and Malignant Soft Tissue Tumors Treatment market report assists clients to stay ahead of the time and competition.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Benign and Malignant Soft Tissue Tumors Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Sizing

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[rohans18]

Benign and Malignant Soft Tissue Tumors Treatment Market Analysis and Forecast to 2029

Global Benign and Malignant Soft Tissue Tumors Treatment Market, By Types Benign Schwannoma, Desmoid Tumor, Lipoblastoma, Lipoma, Solitary, Uterine Leiomyoma, Clear Cell Sarcoma, Dermatofibrosarcoma Protuberans, Ewing Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Liposarcoma, Myxoid, Liposarcoma, Well Differentiated, Alveolar Rhabdomyosarcoma, Synovial Sarcoma, Others), Treatment (Medical Therapy, Surgical Therapy, Postoperative Therapy, Long Term Monitoring, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

The consistent Benign and Malignant Soft Tissue Tumors Treatment market report analyzes many points that help businesses to solve the toughest questions in less time. The major topics of this business report are global growth trends, market share by manufacturers, market size by type, market size by application, production by region, consumption by region, company profiles, market forecast, value chain and sales channels analysis, opportunities & challenges, threat and affecting factors. The report gives market definition in the form of market driving factors and market restraints which helps estimating the demand of particular product depending on several aspects. Benign and Malignant Soft Tissue Tumors Treatment market survey report studies the global market status and forecast, categorizes the global market size, market value & market volume by key players, type, application, and region.

Key Players

Hoffmann-La Roche Ltd. (Switzerland)

Mylan N.V. (U.S.)

Teva Pharmaceutical Industries Ltd. (Israel)

Sanofi (France)

Pfizer Inc. (U.S.)

GSK plc (U.K.)

Novartis AG (Switzerland)

Bayer AG (Germany)

Lilly (U.S.)

Merck & Co., Inc. (U.S.)

Sun Pharmaceutical Industries Ltd. (India)

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-benign-and-malignant-soft-tissue-tumors-treatment-market

One of the principal objectives of a high-ranking Benign and Malignant Soft Tissue Tumors Treatment industry report is to analyze and study the global sales, value, status, and forecast. The market report also analyzes the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. The report assists to define, describe and forecast the market by type, application and region. It estimates the region that is foretold to create the most number of opportunities in the global Benign and Malignant Soft Tissue Tumors Treatment market. This market research report comprises of estimations of CAGR values which are quite significant and aids businesses to decide upon the investment value over the time period. An insightful Benign and Malignant Soft Tissue Tumors Treatment market report assists clients to stay ahead of the time and competition.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Benign and Malignant Soft Tissue Tumors Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Sizing

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Middle East and Africa Thyroid Ablation Devices Market

Europe Thyroid Ablation Devices Market

U.S. Dermatology Drugs Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[ourhaileydavies]

A Rare Origin of Supraclavicular Mass in a Ten-Month-Old Child: Case Report of Lipoblastoma-Juniper publishers

Introduction

Lipoblastoma is a rare benign tumor arising from embryonic white fat which occurs in the early childhood and accounts for up to 30% of adipocytic tumors in children while true lipomas account for 60% of all cases [1]. It usually arises on the extremities and considered as a rare cause of a pediatric head and neck masses. To notice that less than 100 cases of lipoblastomas- all locations- have been reported in literature till now, whereas, head and neck involvement has been reported in only very few cases [2]. In the Hospital University Ibn Rochd, we admitted a ten month child with lipoblastoma arising from the supraclavicular area. A significant risk of invading the subclavian vessels, the brachial plexus and the thoracic duct in contact was near.

Case Report

A 10-month-old girl, with no relevant medical or surgical history, brought by her parents to the outpatient ENT department for painless left side neck mass growing progressively over the last 5 months, with no sign of compression, in a context of a conservation of general state. On physical examination, there was a painless, non-pulsatile, solid to firm left-sided cervical mass in the supraclavicular area measuring approximately 6cm of large diameter, fixed to the underlying structures, mobile relative to the overlying skin (Figure 1), with no inflammatory signs neither was a lymph node hypertrophy. The rest of clinical examination was within normal limits with no abnormal laboratory findings. Ultrasonography revealed a homogeneous, hyperechogenic mass with a peripheral vascularization, plunging into the left supraclavicular area evocative of either hemangioma or lipoblastoma. We completed by neck CT scan which revealed a well limited supraclavicular lobulated mass encroaching upon the sternocleidomastoid muscle, with a greasy density similar to that of the subcutaneous fat in which some enhancement was visible, crossed by internal septa, measuring 63x42x40mm.The mass came into contact with the clavicle without bone lysis, also with the subclavian blood vessels which remain permeable (Figure 2). The biopsy of the mass confirmed the diagnosis of lipoblastoma. A multidisciplinary surgery (Otorhinolaryngologist and Pediatric surgeon) was considered

Per-operatively, the lesion was found to be well encapsulated fixed to clavicle, in contact with the branches of the brachial plexus posteriorly. Complete surgical resection of the mass with an under-periosteum dissection without cleidotomy was performed, the subclavian vein was tightly adherent to the mass which was delicately dissected, and the brachial plexus was seen and preserved (Figure 3). Histological examination showed an adipose lesion, divided into lobules by fibrous septa. The adipose tissue consisted of mature adipocytes of various size and few lipoblasts. These findings were compatible with lipoblastoma. The postoperative period was uneventful, one-year follow-up found no local recurrence.

Discussion

The term “lipoblastoma” was coined by Jaffe [3] in 1926 to describe an atypical lipomatous lesion that consisted of cells resembling embryonic white fat [3]. This term was intended to differentiate these lesions from common lipomas, which contain no lipoblasts. Chung & Enzinger [1] described two forms: lipoblastoma as a localized circumscribed type which represents approximately 70% of cases and lipoblastomatosis for the diffuse multicentric variant (about 30% of cases) which is a deeply located, poorly circumscribed lesion with infiltrative growth pattern that may affect surrounding muscle structures, this latter is more difficult to remove completely [1,4]. It commonly arises from the extremities (36 72%) and the trunk (20 50%), and less commonly in the head and neck (10 15%) [2]. Within this latter, the neck is the most common location, other locations may also be included as the parotid gland, cheek, skin and orbit [5,6]. It occurs exclusively in infants and children, with 90% of the cases in children under 3 years of age, with the median age of onset being 1 year. It shows a male preponderance (3:1) and a rapid growth rate [6].

Usually, it presents as a painless, progressively growing mass if localized superficially. Symptoms are related to the location and size or mass effect of the lesion. Its rapid growth may cause compressive symptoms such as an airway obstruction and respiratory symptoms that have been described in patients with pleural, mediastinal, pulmonary, and lower neck lipoblastomas [5,7].

The presumptive diagnosis is performed by imaging: Ultrasonography, CT or MRI being more sensitive by showing the characteristics of the mass components [7]. Imaging exhibits the precise location of the lesion and its extent to the surrounding structures which helps in planning surgical resection, however, it cannot differentiate lipomatous tumors which make these ones radiologically indistinguishable [8]. Therefore, the definitive diagnosis is made histologically. Moreover, recent cytogenetic analysis revealed specific chromosomal abnormalities in adipose tissue tumors which may lead to accurate diagnosis [2,9].

The most important differential diagnosis of lipoblastoma is myxoid liposarcoma. Since the distinction between the twoentities cannot be performed on imaging. The age of the patient is significant. Liposarcomas are extremely rare in patients less than 10 years of age. Histology can differentiate on the basis of architectural changes and cytogenetic analysis displays a characteristic rearrangement of the long arm of chromosome 8 (8q11-13) affecting PLAG1 in lipoblastoma, when myxoid liposarcoma shows a t(12;16) (q13;p11) translocation [10-13].

Dilley et al. [14] had reviewed 24 patients who presented to a single institution over a 15 year period. Of these 24 patients, only 4 had tumor in the head and neck region. The tumor may present as a focal or diffuse lesion with the former being more common. It has also been mentioned that focal lesions usually do not require further surgery following initial resection. Patients with lipoblastoma may present with various symptoms depending upon its site. Rasmussen et al. [15], mentioned a case of cervical lipoblastoma causing intermittent airway obstruction. Farrugia et al. [16] reported another case of lipoblastoma of the neck which was presented as a rapidly enlarging mass, mimicking cystic hygroma. Eveline Bruyeera [6] reported three cases of head and neck lipoblastoma. The outcome of three patients was favorable after complete surgical resection. K Premkumar [2] recently reported another case of an extensive tumor located over the nape of the neck that causes a restriction of neck movement

Lipoblastoma exhibits a propensity to invade locally. If not excised early, it may enlarge and infiltrate the various surrounding structures. Various pressure symptoms may occur which can lead to life threatening complications as noted hereinbefore [2].

The mainstay of treatment is complete non-mutilating resection of the tumor to avoid recurrence. If the entire tumor cannot be safely removed at the time of initial resection, a staged approach is recommended. [17] The prognosis is excellent, and the recurrence rate is less than 25% being largely attributed to the infiltrative form ‘lipoblastomatosis’. The evolution is unpredictable, spontaneous resolution and maturation into lipoma may occur, but metastases still not reported so far [17,18].

Conclusion

Head and neck lipoblastoma are a rare childhood tumor, usually presenting as a progressive painless mass, rarely causing airway obstruction, nerve or vascular compression. Through our case, we aimed to shed light on lipoblastomas as a differential diagnosis of rapidly growing soft fatty masses of children within this region.

To know more about Open Access Journal of Head Neck & Spine Surgery please click on:

https://juniperpublishers.com/jhnss/index.php

To know more about Open access Journals Publishers please click on : Juniper Publishers

To know more about juniper publishers: https://juniperpublishers.business.site/